Suchergebnisse - "Nguyen, Bach"

PubPharm (30)

1

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Dickinson, L. | Gurjar, R. | Stöhr, W. | +113

2

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection : Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2018

von Cahn, P. | Sax, P. | Squires, K. | +13

3

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection : a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2017

von Cahn, P. | Kaplan, R. | Sax, P. | +122

CommentIn: Lancet HIV. 2017 Nov;4(11):e476-e477. - PMID 28918878

4

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1 : a substudy of the NEAT001/ANRS143 randomised trial

enthalten in: The lancet. HIV | 2015

von Bernardino, J. | Mocroft, A. | Mallon, P. | +115

CommentIn: Lancet HIV. 2015 Nov;2(11):e452-3. - PMID 26520920

5

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection

enthalten in: Antiviral therapy | 2015

von Eron, J. | Cooper, D. | Steigbigel, R. | +8

6

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2014

von Raffi, F. | Babiker, A. | Richert, L. | +117

CommentIn: Lancet. 2014 Nov 29;384(9958):1908-10. - PMID 25103175

7

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies : final results of two randomised, placebo-controlled trials

enthalten in: The Lancet. Infectious diseases | 2013

von Eron, J. | Cooper, D. | Steigbigel, R. | +116

CommentIn: Lancet Infect Dis. 2013 Jul;13(7):561-2. - PMID 23664332

8

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients : 48-week results from the REALMRK Study

enthalten in: AIDS research and human retroviruses | 2013

von Squires, K. | Bekker, L. | Eron, J. | +56

9

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients : final 5-year results from STARTMRK

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2013

von Rockstroh, J. | DeJesus, E. | Lennox, J. | +80

10

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection : final results of a randomized, controlled, phase II study (Protocol 004)

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2012

von Gotuzzo, E. | Markowitz, M. | Ratanasuwan, W. | +36